Bio-Rad Laboratories (NYSE:BIO) Downgraded by Zacks Research to Strong Sell

Posted by Brian Himes on Jul 15th, 2026

Zacks Research lowered shares of Bio-Rad Laboratories (NYSE:BIO – Free Report) from a hold rating to a strong sell rating in a research note released on Monday,Zacks.com reports.

Several other equities analysts have also recently issued reports on BIO. Wells Fargo & Company dropped their price objective on shares of Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating on the stock in a research note on Friday, May 1st. Weiss Ratings cut shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Citigroup downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their target price for the company from $375.00 to $300.00 in a report on Tuesday, April 7th. Finally, Royal Bank Of Canada initiated coverage on shares of Bio-Rad Laboratories in a research note on Friday, May 15th. They set an “outperform” rating and a $320.00 price target on the stock. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $303.33.

Get Our Latest Analysis on Bio-Rad Laboratories

Bio-Rad Laboratories Stock Up 0.3%

Bio-Rad Laboratories stock opened at $298.45 on Monday. The stock has a 50 day moving average of $286.34 and a two-hundred day moving average of $287.55. Bio-Rad Laboratories has a twelve month low of $236.73 and a twelve month high of $343.12. The stock has a market capitalization of $7.99 billion, a price-to-earnings ratio of 49.17 and a beta of 1.08. The company has a current ratio of 3.21, a quick ratio of 2.37 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIO – Get Free Report) last released its earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). Bio-Rad Laboratories had a net margin of 6.52% and a return on equity of 3.56%. The company had revenue of $592.10 million during the quarter, compared to analyst estimates of $589.91 million. During the same period in the previous year, the firm posted $2.54 EPS. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. As a group, research analysts expect that Bio-Rad Laboratories will post 9.42 earnings per share for the current year.

Institutional Trading of Bio-Rad Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in BIO. Assenagon Asset Management S.A. raised its holdings in Bio-Rad Laboratories by 57.8% during the second quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock worth $68,478,000 after purchasing an additional 85,393 shares during the last quarter. Empowered Funds LLC grew its holdings in Bio-Rad Laboratories by 38.0% in the first quarter. Empowered Funds LLC now owns 2,168 shares of the medical research company’s stock valued at $604,000 after purchasing an additional 597 shares during the last quarter. Amundi grew its holdings in Bio-Rad Laboratories by 1,763.4% in the first quarter. Amundi now owns 38,778 shares of the medical research company’s stock valued at $10,809,000 after purchasing an additional 36,697 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Bio-Rad Laboratories by 22.9% in the first quarter. California State Teachers Retirement System now owns 21,932 shares of the medical research company’s stock valued at $6,114,000 after buying an additional 4,082 shares in the last quarter. Finally, Royal Bank of Canada increased its position in shares of Bio-Rad Laboratories by 16.9% in the first quarter. Royal Bank of Canada now owns 17,198 shares of the medical research company’s stock valued at $4,794,000 after buying an additional 2,487 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company’s stock.

About Bio-Rad Laboratories

(Get Free Report)

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.